STOCKS TELEGRAPH

Tag: Exicure stock

  • Exicure (XCUR) Stock Sees Gains After-Hour On Key Study Completion

    Exicure (XCUR) Stock Sees Gains After-Hour On Key Study Completion

    During Friday’s extended trading session, Exicure, Inc. (NASDAQ: XCUR) saw a significant increase, closing at $7.80 after rising 13.28%. Following the company’s confirmation of the accomplishment of a crucial clinical research milestone, this increase occurred.

    Phase 2 Clinical Trial Milestone Completed

    The biotechnology business reported that the final patient visit in its current Phase 2 clinical study (NCT05561751) was successfully completed. The safety and effectiveness of GPC-100 (burixafor) in conjunction with propranolol and G-CSF for patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) are assessed in this research. Exicure anticipates this trial’s topline findings in the fourth quarter of 2025.

    GPC-100’s Potential for Stem Cell Mobilization

    A very specific small molecule antagonist of the chemokine receptor CXCR4, which is essential for keeping hematopoietic stem cells in the bone marrow niche, is GPC-100 (burixafor). GPC-100 may help mobilize these stem cells into peripheral circulation for collection and further ASCT operations by inhibiting CXCR4. GPCR Therapeutics, Inc. was the original developer of the chemical, which Exicure acquired in January 2025 and added to their pipeline.

    Beyond multiple myeloma, GPC-100 is under consideration for acute myeloid leukemia (AML) and other medical conditions where improved stem cell mobilization could enhance treatment outcomes. This includes applications in sickle cell disease, rare disorders requiring autologous transplant, and in cell and gene therapy programs.

    Differentiated Clinical Performance and Patient Benefits

    The ongoing randomized, open-label, multicenter study is designed to determine whether GPC-100 can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into peripheral blood for ASCT procedures. Data presented at ASH 2024 indicated that GPC-100 offers a faster mobilization rate compared to currently approved agents.

    Typically, mobilization requires patients to receive injections the night before stem cell collection, creating logistical burdens. In contrast, GPC-100 can be administered just 45 minutes before the procedure, resulting in efficient mobilization and enhancing patient experience.

    Exicure is also advancing plans for a Phase 1 AML study and engaging in discussions for potential collaborations to expand GPC-100’s use in cell and gene therapy applications.

  • Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval

    Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval

    Shares of Exicure, Inc. (NASDAQ: XCUR) rose 4.59% to $13.66 during premarket trading. This rise follows the company’s announcement that it has been granted a new patent by the Australian Patent Office, strengthening its position in the study of cancer treatments.

    Patent Strengthens Cancer Treatment Strategy

    Exicure has been granted a patent for “GPCR Heteromer Inhibitors and Uses Thereof,” protecting its innovative approach to cancer treatment that targets GPCRx and CXCR4. The company’s Phase 2 clinical study, which evaluates the combined effectiveness of GPC-100 and propranolol for patients with multiple myeloma, is supported by this patent.

    By strengthening its top clinical program and opening the door for additional potent treatment options, the recently granted patent expands Exicure’s intellectual property protection.

    By concurrently targeting CXCR4 and ADRB2, the study aims to increase hematopoietic stem cell mobility and boost the efficacy of CXCR4 inhibitors such as GPC-100. Taiwan, Japan, and the United States have previously awarded similar patents, while other applications are still pending in important international markets.

    Purchasing GPCR Therapeutics USA Strategically

    Through a Share Purchase Agreement, Exicure has strategically purchased GPCR Therapeutics USA Inc., a California-based subsidiary of GPCR Therapeutics Inc., a Korean company. Concurrent with the agreement’s execution, the purchase was completed, adding GPCR USA to XCUR’s portfolio.

    A Licensing Agreement Increases Efforts at Commercialization

    Exicure and GPCR Therapeutics Inc. signed a License and Collaboration Agreement (L&C Agreement) after the purchase. As per this arrangement, XCUR is in charge of advancing and bringing GPCR-related technology to market. According to the agreements, milestone payments must be linked to significant sales, clinical, and regulatory accomplishments.

    Furthermore, Exicure shall pay recurrent royalties on net sales from the licensed technology at a minimum rate of 10%. XCUR continues to solidify its place in the biotechnology industry by promoting cutting-edge cancer treatment options with this most recent patent and strategic alliance.

  • Exicure (XCUR) Stock Surges Following Acquisition Agreement

    Exicure (XCUR) Stock Surges Following Acquisition Agreement

    Exicure, Inc. (NASDAQ: XCUR) has experienced a significant surge in its stock value following the definitive share purchase agreement with South Korean corporation GPCR Therapeutics Inc. As of the latest market update, XCUR shares traded at $13.23, a substantial 27.53% increase, reflecting investor confidence in the acquisition’s potential to strengthen Exicure’s position in the biotechnology sector.

    Formalizing the Acquisition and Collaborative Partnership

    On January 19, 2025, Exicure finalized the acquisition of all equity securities of GPCR Therapeutics USA Inc., the California-based subsidiary of GPCR Therapeutics Inc. The transaction coincided with the Share Purchase Agreement. Previously, GPCR USA operated as a wholly owned subsidiary. Concurrently, Exicure and GPCR established a License and Collaboration Agreement (L&C Agreement) to develop and commercialize GPCR’s proprietary technologies, patents, and intellectual property.

    Financial Implications and Milestone Structure

    The L&C Agreement details a structured financial arrangement, including milestone payments from Exicure to GPCR upon achieving predefined objectives in clinical trials, marketing authorizations, and net sales. It also stipulates recurring royalty payments from Exicure to GPCR, based on a minimum of 10% of net sales, as detailed in the agreement. This structure ensures ongoing collaboration and shared financial interest in the successful development and commercialization of the acquired technologies.

    Strategic Expansion and Clinical Pipeline Enhancement

    This acquisition follows a previous Memorandum of Understanding (MOU) outlining the intended acquisition of GPCR USA, technology transfer, and collaborative research on GPCR Therapeutics’ drug development pipelines. Exicure gains access to key technical personnel and technology related to GPCR Therapeutics’ CXCR4 inhibitor, currently in FDA Phase 2 trials, along with associated patents and intellectual property.

    This positions Exicure to advance as a clinical-stage biotech company, leveraging acquired expertise and promising clinical pipelines. GPCR Therapeutics aims to finalize ongoing stem cell mobilizer (SCM) trials for multiple myeloma patients and prepare for acute myeloid leukemia (AML) studies. The target market for the Phase 2 trials is estimated between $1 billion and $2 billion annually.

    Market Performance within the Biotechnology Sector

    Market data shows XCUR with an ST score of 39 and an SMA200 exceeding 94% within the Biotechnology industry. While demonstrating strong performance, other peer stocks, like MNPR and CMRX, exhibit higher ST scores and SMA200 values above 100%. For a short selection of stocks that may be compared further, see our screener.

  • Exicure (XCUR) Stock Gains Momentum Pre-Hours With Strategic Developments

    Exicure (XCUR) Stock Gains Momentum Pre-Hours With Strategic Developments

    Shares of Exicure, Inc. (NASDAQ: XCUR) are witnessing remarkable growth, climbing 11.18% pre-market to $20.55 following a 69.24% surge in the previous trading session, which closed at $18.38. The spike in XCUR stock price is attributed to pivotal equity transactions and operational shifts that signal a transformative phase for the biotechnology company.

    Equity Transaction with HiTron Systems Inc.

    On November 12, 2024, Exicure finalized an agreement with HiTron Systems Inc. to sell 433,333 common shares at $3.00 per share, raising $1.3 million. This transaction, executed without requiring stockholder approval, granted HiTron approximately 16.6% ownership of outstanding XCUR common stock. Additionally, HiTron gained the right to appoint two board directors and designated its CEO as its chief restructuring officer, underscoring its strategic influence in the company.

    Proposed Majority Stake Acquisition

    Exicure continued negotiations with HiTron for a larger investment, culminating in a November 13, 2024, agreement to issue 2.9 million additional shares for $8.7 million. This proposal, contingent on stockholder approval at a special meeting, would result in HiTron owning a 61% majority stake in XCUR, effectively altering control of the company under Nasdaq regulations. Proceeds from this deal are earmarked for corporate purposes and business development.

    Transition from Research to Strategic Realignment

    Exicure’s evolution reflects a departure from its traditional focus on nucleic acid therapies. Since halting preclinical and R&D activities in September 2022, the company has prioritized maximizing shareholder value through strategic alternatives. The proposed agreement with HiTron represents a significant pivot in this effort, offering both capital infusion and leadership restructuring.

    Regulatory and Operational Framework

    The purchase agreement includes standard representations and closing conditions, such as stockholder approval, compliance with Nasdaq guidelines, and indemnification provisions. A concurrent registration rights agreement obliges XCUR to file a registration statement for HiTron’s shares within 60 days post-closing.

    Additional covenants ensure a 90-day lock-up period and continuation of director and officer insurance policies. If approved, this strategic partnership marks a critical milestone for Exicure, as it seeks to redefine its operational trajectory and unlock new opportunities under HiTron’s majority ownership.

  • ‎26 stocks making the biggest moves premarket today

    ‎26 stocks making the biggest moves premarket today

    ‎Mereo BioPharma Group plc (MREO) stock plunged -7.78% to $3.32 in the pre-‎market trading after declaring collaboration and license agreement with Ultragenyx Pharmaceutical ‎Inc. (RARE), for Setrusumab in Osteogenesis Imperfecta.‎

    ‎Naked Brand Group Limited (NASDAQ: NAKD) shares are trading up ‎‎11.45% ‎at ‎‎$0.2044 at the time of writing. Company’s 52-week ranged between $0.07 to $3.70.‎

    ‎Exela Technologies Inc. (XELA) is down more than -9.79% at $0.4128 in pre-market ‎hours Monday December 21, 2020 following the announcement from the firm that it has entered into ‎a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm. The ‎stock had jumped over 26.10% to $0.46 in the last trading session.‎

    ‎Zomedica Corp. (ZOM) tumbled over -5.22% at $0.1959 in pre-market trading today.‎

    Before the trading started on December 21, 2020, BlackBerry Limited (BB) is down -‎‎3.17% to reach $6.73 after releasing financial results for the three months ended November 30, 2020. It ‎has been trading in a 52-week range of $2.70 to $9.69.‎

    ‎General Electric Company (GE), a Specialty Industrial Machinery company, dropped ‎about -6.11% at $10.15 in pre-market trading Monday after announcing expiration and results of its ‎debt tender offers.‎

    ‎Phunware Inc. (PHUN) lost over -10.38% at $0.95 in pre-‎‎market ‎trading ‎Monday ‎December 21, 2020.‎

    ‎American Airlines Group Inc. (AAL) lost over -7.03% at $15.35 in pre-market trading ‎Monday December 21, 2020.‎

    Before the trading started on December 21, 2020, Carnival Corporation & Plc (CCL) is ‎down -9.79% to reach $19.36. It has been trading in a 52-week range of $7.80 to $51.94.‎

    ‎FuelCell Energy Inc. (FCEL) stock moved down -4.3 percent to $8.9 in the pre-‎market trading after declaring that state regulators have improperly rescinded RFP awards for three ‎fuel cell projects previously selected in the Shared Clean Energy Facility program, putting its state high ‎tech manufacturing job growth at risk.‎

    ‎Exicure Inc. (XCUR) stock soared 7.04% to $2.13 in the pre-‎‎market ‎trading. ‎The ‎most ‎recent rating by BMO Capital Markets, on December 18, 2020, is ‎an ‎Outperform.‎

    ‎Genius Brands International Inc. (GNUS), a Entertainment company, rose about ‎‎3.18% at $1.62 in pre-market trading Monday. The firm recently revealed that it has licensed streaming ‎and select video-on-demand rights to the hit family series, The Wubbulous World of Dr. Seuss (20 x ‎‎22’), from The Jim Henson Company on Kartoon Channel!‎

    ‎SolarWinds Corporation (NYSE: SWI) shares are trading ‎up ‎‎6.7% ‎at ‎‎$15.13 ‎at ‎the ‎time of writing. Company’s 52-week ranged between $11.50 ‎to ‎‎$24.34. ‎Analysts ‎have ‎a ‎consensus ‎price target of $26. ‎

    ‎Norwegian Cruise Line Holdings Ltd. (NCLH) lost over -10.01% at $22.66 in pre-‎market trading Monday December 21, 2020 after reporting that it has closed its previously announced ‎private offering of $850 million aggregate principal amount of its 5.875% senior notes due 2026 (the ‎‎“Notes”).‎

    Before the trading started on December 21, 2020, Nokia Corporation (NOK) is down ‎‎-5.25% to reach $3.79. The company recently declared that it has launched 5G services with Polkomtel, ‎operator of the Plus network, in the capital city of Warsaw as well as other major cities in the eastern ‎part of the country. It has been trading in a 52-week range of $2.34 to $5.14.‎

    ‎Corbus Pharmaceuticals Holdings Inc. (CRBP) is up more than 12.0% at $1.68 in pre-‎‎‎‎‎‎‎‎market hours Monday December 21, 2020. The stock had jumped ‎over ‎‎11.11% ‎to ‎‎$1.50 ‎in ‎the ‎last ‎trading session.‎

    ‎Schlumberger Limited (NYSE: SLB) shares are trading down -6.95% at $20.76 at the ‎time of writing. The firm will hold a conference call on January 22, 2021 to discuss the results for the ‎fourth quarter and full year ending December 31, 2020. Company’s 52-week ranged between $11.87 to ‎‎$41.14.‎

    ‎Exxon Mobil Corporation (NYSE: XOM) shares are trading down -5.27% ‎at ‎‎$40.48 ‎at ‎the time of writing. Company’s 52-week ranged between $30.11 to $71.37. Analysts ‎have ‎a ‎consensus ‎price target of $52.‎

    ‎Transocean Ltd. (RIG) is down more than -14.92% at $2.11 in pre-market hours ‎Monday December 21, 2020 after announcing successful court ruling granting its motion for summary ‎judgment and holding internal reorganization did not violate indenture. The stock had dropped over -‎‎3.50% to $2.48 in the last trading session.‎

    ‎Simon Property Group Inc. (SPG) tumbled over -5.07% at $81.1 in pre-market ‎trading today. The firm recently declared a common stock dividend for the fourth quarter 2020.‎
    ‎
    ‎Energy Transfer LP (ET), a Oil & Gas Midstream company, dropped about -‎‎‎‎5.9% ‎at ‎‎$6.38 in pre-market trading Monday.‎

    ‎Cinedigm Corp. (CIDM) stock moved up 4.11 percent to $0.798 in the pre-market ‎trading after revealing the launch of The Bob Ross Channel on the Roku platform.‎

    Before the trading started on December 21, 2020, Coty Inc. (COTY) is down -6.15% ‎to reach $6.56. The company lately reported two additions to its Board of Directors with the ‎appointments of Anna Adeola Makanju and Mariasun Aramburuzabala Larregui. It has been trading in ‎a 52-week range of $2.65 to $13.01.‎

    ‎JPMorgan Chase & Co. (JPM) gained over 2.24% at $121.75 in pre-‎‎‎‎market ‎trading ‎Monday December 21, 2020. ‎

    ‎Apache Corporation (NASDAQ: APA) shares are trading down -11.29% at $13.6 at ‎the time of writing after announcing the donation of more than 64,000 trees to 56 nonprofit partner ‎organizations through the annual Apache Tree Grant Program. Company’s 52-week ranged between ‎‎$3.80 to $33.77. Analysts have a consensus price target of $16.‎